NASDAQ:NEO NeoGenomics (NEO) Stock Price, News & Analysis $7.21 +0.13 (+1.84%) Closing price 04:00 PM EasternExtended Trading$7.34 +0.13 (+1.73%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About NeoGenomics Stock (NASDAQ:NEO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NeoGenomics alerts:Sign Up Key Stats Today's Range$6.95▼$7.2350-Day Range$4.84▼$7.6252-Week Range$4.72▼$19.11Volume2.54 million shsAverage Volume2.16 million shsMarket Capitalization$931.39 millionP/E RatioN/ADividend YieldN/APrice Target$12.75Consensus RatingHold Company Overview NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida. Read More NeoGenomics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreNEO MarketRank™: NeoGenomics scored higher than 70% of companies evaluated by MarketBeat, and ranked 310th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingNeoGenomics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 4 buy ratings, 8 hold ratings, and no sell ratings.Amount of Analyst CoverageNeoGenomics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about NeoGenomics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for NeoGenomics are expected to grow in the coming year, from ($0.20) to $0.09 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeoGenomics is -8.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeoGenomics is -8.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeoGenomics has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about NeoGenomics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.98% of the float of NeoGenomics has been sold short.Short Interest Ratio / Days to CoverNeoGenomics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeoGenomics has recently increased by 17.56%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeoGenomics does not currently pay a dividend.Dividend GrowthNeoGenomics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.98% of the float of NeoGenomics has been sold short.Short Interest Ratio / Days to CoverNeoGenomics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeoGenomics has recently increased by 17.56%, indicating that investor sentiment is decreasing significantly. News and Social Media3.4 / 5News Sentiment1.15 News SentimentNeoGenomics has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for NeoGenomics this week, compared to 6 articles on an average week.Search Interest14 people have searched for NEO on MarketBeat in the last 30 days. This is an increase of 56% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added NeoGenomics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NeoGenomics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.40% of the stock of NeoGenomics is held by insiders.Percentage Held by Institutions98.50% of the stock of NeoGenomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NeoGenomics' insider trading history. Receive NEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NEO Stock News HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEOAugust 27 at 10:00 AM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEOAugust 25 at 12:17 PM | globenewswire.comWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was projected. According to Porter Stansberry, this is panic-level borrowing… and a clear sign we’re nearing America’s financial breaking point. In his latest emergency briefing, Porter outlines why the cracks in our system are widening fast—and how Trump’s policies may be accelerating the collapse. More importantly, he reveals three moves you can make now to protect and potentially grow your wealth before the levee breaks.August 28 at 2:00 AM | Porter & Company (Ad)INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEOAugust 22, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEOAugust 21, 2025 | globenewswire.comNEO Home Loans Division Leader, Josh Mettle, Helps 82 Families in One Month Citing Technology Efficiencies and Team SynergyAugust 18, 2025 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEOAugust 17, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEOAugust 16, 2025 | prnewswire.comSee More Headlines NEO Stock Analysis - Frequently Asked Questions How have NEO shares performed this year? NeoGenomics' stock was trading at $16.48 at the start of the year. Since then, NEO shares have decreased by 56.3% and is now trading at $7.21. How were NeoGenomics' earnings last quarter? NeoGenomics, Inc. (NASDAQ:NEO) issued its quarterly earnings data on Tuesday, April, 29th. The medical research company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.02) by $0.06. The company's revenue for the quarter was up 7.6% on a year-over-year basis. Read the conference call transcript. Does NeoGenomics have any subsidiaries? The following companies are subsidiaries of NeoGenomics: Inivata Limited, Trapelo Health, Genesis Acquisition Holding Corp, Genoptix, Clarient Inc, GE Medical Holding AB., Path Labs LLC, and others. Who are NeoGenomics' major shareholders? NeoGenomics' top institutional investors include Greenhouse Funds LLLP (5.75%), First Light Asset Management LLC (5.30%), American Century Companies Inc. (2.72%) and Geode Capital Management LLC (2.44%). Insiders that own company stock include Jeffrey Scott Sherman, Warren Stone, Stephen M Kanovsky, Alicia C Olivo, Anthony P Zook, David Brian Perez, Lynn A Tetrault and Michael Aaron Kelly. View institutional ownership trends. How do I buy shares of NeoGenomics? Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NeoGenomics own? Based on aggregate information from My MarketBeat watchlists, some other companies that NeoGenomics investors own include Humana (HUM), American Water Works (AWK), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR) and AU Optronics (AUOTY). Company Calendar Last Earnings4/29/2025Today8/28/2025Next Earnings (Estimated)11/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBusiness Services Current SymbolNASDAQ:NEO CIK1077183 Webwww.neogenomics.com Phone(239) 768-0600Fax239-690-4237Employees2,200Year Founded2002Price Target and Rating Average Price Target for NeoGenomics$12.75 High Price Target$22.00 Low Price Target$8.00 Potential Upside/Downside+78.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($0.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$78.73 million Net Margins-15.10% Pretax Margin-15.30% Return on Equity-2.72% Return on Assets-1.54% Debt Debt-to-Equity Ratio0.40 Current Ratio3.92 Quick Ratio3.58 Sales & Book Value Annual Sales$660.57 million Price / Sales1.40 Cash Flow$0.47 per share Price / Cash Flow15.27 Book Value$6.61 per share Price / Book1.08Miscellaneous Outstanding Shares129,180,000Free Float126,079,000Market Cap$921.70 million OptionableOptionable Beta1.54 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:NEO) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeoGenomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeoGenomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.